

Reference:	FOI.12842.23
Subject:	Renal Cell Carcinoma (RCC) and Melanoma treatment
Date of Request:	10 October 2023

Requested:

1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- Avelumab + Axitinib
- Axitinib
- Cabozantinib
- Everolimus
- Lenvatinib + Everolimus
- Nivolumab monotherapy
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Pembrolizumab + Lenvatinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anti-cancer therapy
- Palliative care only

2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib
- Dabrafenib
- Dabrafenib AND Trametinib
- Dacarbazine
- Denosumab
- Encorafenib AND Binimetinib
- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib AND Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

3. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for palliative care for questions 1 and 2, the UHB would need to undertake a manual trawl of the medical records of patients that are receiving palliative care, to identify any information that would fulfil your request, as this is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds below.

1. The UHB provides, within the table below, the number of RCC patients that have received the treatments listed, as recorded on the ChemoCare system, during the period 1 July to 30 September 2023.

Medication	Number
Avelumab + Axitinib	0
Axinitib	0
Cabozantinib	*
Everolimus	0
Lenvantinib + Everolimus	0
Nivolumab monotherapy	10
Nivolumab + Cabozantinib	0
Nivolumab + Ipilimumab	*
Pazopanib	0
Pembrolizumab monotherapy	*
Pembrolizumab + Axitinib	0
Pembrolizumab + Lenvatinib	0
Radiotherapy only	**Not held
Sunitinib	0
Temsirolimus	0
Tivozanib	0
Other active systemic anti-cancer therapy	0
Palliative care only	Section 12 exemption applied

**The UHB regrets to inform you that it does not hold the information requested for Radiotherapy. The UHB’s patients that require Radiotherapy are seen and treated in Singleton Hospital, within Swansea Bay University Health Board (SBUHB) and are managed by them. Therefore, we recommend that you redirect this part of your request to the Freedom of Information Team at SBUHB who may be able to help you further. The contact details are as follows:

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.

2. The UHB provides, within the table below, the number of melanoma patients that have received the treatments listed, as recorded on the ChemoCare system, during the period 1 July to 30 September 2023.

Medication	Number
Cobimetinib	0
Dabrafenib	0
Dabrafenib AND Trametinib	0
Dacarbazine	0
Denosumab	0
Encorafenib AND Binimetinib	0
Ipilimumab	0
Ipilimumab AND Nivolumab	*
Nivolumab	*
Pembrolizumab	14
Trametinib	0
Vemurafenib	0
Vemurafenib AND Cobimetinib	0
Other active systemic anti-cancer therapy	0
Palliative care only	Section 12 exemption applied

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FOIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

3. The UHB confirms that it is not currently participating in any clinical trials for the treatment of Melanoma.